All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

deferiprone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	4188	30652-11-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: deferiprone deferione ferriprox	a chelating agent with an affinity for ferric ion (iron III) indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes Molecular weight: 139.15 Formula: C7H9NO2 CLOGP: -0.90 LIPINSKI: 0 HAC: 3 HDO: 1 TPSA: 40.54 ALOGS: 0.29 ROTB: 0 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,ITK,JAK1,JAK2,KIT,MAP3K21,MAP3K7,MAPK12,MAPK7,MAPK9,MARK4,MTOR,NTRK2,PDK1,PDK2,PDPK1,PIK3CB,PIK3CD,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1	52
kinase-selectivity-class	ACVR2B,AXL,BRAF,CDK9,DDR1,EIF2AK3,ERBB2,GRK2,MAP2K6,MAPK7,MARK4,SIK2,STK33,TEK	14
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
Aug. 25, 1999	EMA	APOTEX EUROPE BV
Oct. 14, 2011	FDA	APOPHARMA INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Agranulocytosis	264.44	36.85	70	1503	34932	90591942
Sickle cell anaemia with crisis	202.46	36.85	42	1531	7255	90619619
Off label use	111.56	36.85	114	1459	1102138	89524736
Neutropenia	87.30	36.85	52	1521	224852	90402022
Serum ferritin increased	76.23	36.85	19	1554	7362	90619512
Treatment noncompliance	62.61	36.85	26	1547	51701	90575173
Death	60.20	36.85	55	1518	456496	90170378
Neuroleptic malignant syndrome	54.29	36.85	17	1556	15079	90611795

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Agranulocytosis	164.30	31.83	53	1217	30559	42589506
Death	64.49	31.83	74	1196	471111	42148954
Neutropenia	50.61	31.83	44	1226	199387	42420678
Sickle cell anaemia with crisis	45.60	31.83	13	1257	4877	42615188
Off label use	38.62	31.83	68	1202	638267	41981798
Serum ferritin increased	36.53	31.83	12	1258	7207	42612858

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Agranulocytosis	391.03	30.77	113	2309	61647	110525230
Sickle cell anaemia with crisis	155.01	30.77	37	2385	9508	110577369
Neutropenia	130.33	30.77	88	2334	374532	110212345
Off label use	126.33	30.77	158	2264	1500027	109086850
Death	122.13	30.77	109	2313	698760	109888117
Serum ferritin increased	76.04	30.77	22	2400	11825	110575052
Treatment noncompliance	71.76	30.77	34	2388	72956	110513921
Neuroleptic malignant syndrome	36.95	30.77	17	2405	34042	110552835
Endocrine disorder	32.59	30.77	7	2415	1117	110585760
Prescribed overdose	31.25	30.77	21	2401	87560	110499317

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V03AC02	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Iron chelating agents
FDA MoA	N0000000144	Iron Chelating Activity
FDA EPC	N0000175522	Iron Chelator
MeSH PA	D002614	Chelating Agents
MeSH PA	D007502	Iron Chelating Agents
MeSH PA	D064449	Sequestering Agents
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:38157	iron chelator
CHEBI has role	CHEBI:48407	antiparkinson drug
CHEBI has role	CHEBI:50267	protective agent
CHEBI has role	CHEBI:64946	anti-HIV agent
CHEBI has role	CHEBI:75835	anti-anaemic agent
CHEBI has role	CHEBI:231911	renoprotective agent

Related Drugs by ATC class:

V03AC Iron chelating agents 2 drugs

deferasiroxdeferoxamine

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Iron overload	indication	60737008
beta Thalassemia	indication	65959000	DOID:12241

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.54	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
100MG/ML	FERRIPROX	CHIESI	N208030	Sept. 9, 2015	RX	SOLUTION	ORAL	8703156	Oct. 26, 2029	METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD
80MG/ML	FERRIPROX	CHIESI	N208030	April 20, 2018	DISCN	SOLUTION	ORAL	8703156	Oct. 26, 2029	METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD
1GM	FERRIPROX	CHIESI	N212269	May 19, 2020	RX	TABLET	ORAL	10780055	Oct. 25, 2038	METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD
1GM	FERRIPROX	CHIESI	N212269	May 19, 2020	RX	TABLET	ORAL	10940115	Oct. 25, 2038	METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD
1GM	FERRIPROX	CHIESI	N212269	May 19, 2020	RX	TABLET	ORAL	11357731	Oct. 25, 2038	METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD
1GM	FERRIPROX	CHIESI	N212269	May 19, 2020	RX	TABLET	ORAL	11723874	Oct. 25, 2038	METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
1GM	FERRIPROX	CHIESI	N021825	July 25, 2019	RX	TABLET	ORAL	April 30, 2028	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT AND PEDIATRIC PATIENTS 8 YEARS OF AGE AND OLDER WITH SICKLE CELL DISEASE OR OTHER ANEMIAS
1GM	FERRIPROX	CHIESI	N021825	July 25, 2019	RX	TABLET	ORAL	April 30, 2028	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT PATIENTS WITH THALASSEMIA SYNDROMES EXCLUDING ADULT PATIENTS COVERED BY THE INDICATION FOR THALASSEMIA SYNDROMES APPROVED ON OCTOBER 14, 2011
1GM	FERRIPROX	CHIESI	N021825	July 25, 2019	RX	TABLET	ORAL	April 30, 2028	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PEDIATRIC PATIENTS 8 YEARS OF AGE AND OLDER WITH THALASSEMIA SYNDROMES
500MG	FERRIPROX	CHIESI	N021825	Oct. 14, 2011	DISCN	TABLET	ORAL	April 30, 2028	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT AND PEDIATRIC PATIENTS 8 YEARS OF AGE AND OLDER WITH SICKLE CELL DISEASE OR OTHER ANEMIAS
500MG	FERRIPROX	CHIESI	N021825	Oct. 14, 2011	DISCN	TABLET	ORAL	April 30, 2028	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT PATIENTS WITH THALASSEMIA SYNDROMES EXCLUDING ADULT PATIENTS COVERED BY THE INDICATION FOR THALASSEMIA SYNDROMES APPROVED ON OCTOBER 14, 2011
500MG	FERRIPROX	CHIESI	N021825	Oct. 14, 2011	DISCN	TABLET	ORAL	April 30, 2028	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PEDIATRIC PATIENTS 8 YEARS OF AGE AND OLDER WITH THALASSEMIA SYNDROMES
100MG/ML	FERRIPROX	CHIESI	N208030	Sept. 9, 2015	RX	SOLUTION	ORAL	April 30, 2028	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT AND PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH SICKLE CELL DISEASE OR OTHER ANEMIAS
100MG/ML	FERRIPROX	CHIESI	N208030	Sept. 9, 2015	RX	SOLUTION	ORAL	April 30, 2028	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT PATIENTS WITH THALASSEMIA SYNDROMES EXCLUDING ADULT PATIENTS COVERED BY THE INDICATION FOR THALASSEMIA SYNDROMES APPROVED ON OCTOBER 14, 2011
100MG/ML	FERRIPROX	CHIESI	N208030	Sept. 9, 2015	RX	SOLUTION	ORAL	April 30, 2028	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH THALASSEMIA SYNDROMES
80MG/ML	FERRIPROX	CHIESI	N208030	April 20, 2018	DISCN	SOLUTION	ORAL	April 30, 2028	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT AND PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH SICKLE CELL DISEASE OR OTHER ANEMIAS
80MG/ML	FERRIPROX	CHIESI	N208030	April 20, 2018	DISCN	SOLUTION	ORAL	April 30, 2028	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT PATIENTS WITH THALASSEMIA SYNDROMES EXCLUDING ADULT PATIENTS COVERED BY THE INDICATION FOR THALASSEMIA SYNDROMES APPROVED ON OCTOBER 14, 2011
80MG/ML	FERRIPROX	CHIESI	N208030	April 20, 2018	DISCN	SOLUTION	ORAL	April 30, 2028	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH THALASSEMIA SYNDROMES
1GM	FERRIPROX	CHIESI	N212269	May 19, 2020	RX	TABLET	ORAL	April 30, 2028	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT AND PEDIATRIC PATIENTS 8 YEARS OF AGE AND OLDER WITH SICKLE CELL DISEASE OR OTHER ANEMIAS
1GM	FERRIPROX	CHIESI	N212269	May 19, 2020	RX	TABLET	ORAL	April 30, 2028	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT PATIENTS WITH THALASSEMIA SYNDROMES EXCLUDING ADULT PATIENTS COVERED BY THE INDICATION FOR THALASSEMIA SYNDROMES APPROVED ON OCTOBER 14, 2011
1GM	FERRIPROX	CHIESI	N212269	May 19, 2020	RX	TABLET	ORAL	April 30, 2028	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PEDIATRIC PATIENTS 8 YEARS OF AGE AND OLDER WITH THALASSEMIA SYNDROMES

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Deoxyhypusine hydroxylase	Enzyme	Q9BU89	DOHH_HUMAN		IC50	5.30		CHEMBL
Lysine-specific demethylase 6A	Enzyme	O15550	KDM6A_HUMAN		IC50	5.38		CHEMBL
Lysine-specific demethylase 4A	Enzyme	O75164	KDM4A_HUMAN		IC50	5.49		CHEMBL
Lysine-specific demethylase 5C	Enzyme	P41229	KDM5C_HUMAN		IC50	5.25		CHEMBL
Lysine-specific demethylase 2B	Enzyme	Q8NHM5	KDM2B_HUMAN		IC50	5.09		CHEMBL
Lysine-specific demethylase 2A	Enzyme	Q9Y2K7	KDM2A_HUMAN		IC50	5.17		CHEMBL

External reference:

ID	Source
4031179	VUID
N0000183921	NUI
D07416	KEGG_DRUG
4031179	VANDF
C0043832	UMLSCUI
CHEBI:68554	CHEBI
CHEMBL70927	ChEMBL_ID
D000077543	MESH_DESCRIPTOR_UI
DB08826	DRUGBANK_ID
7456	IUPHAR_LIGAND_ID
6958	INN_ID
2BTY8KH53L	UNII
2972	PUBCHEM_CID
11645	RXNORM
117386	MMSL
18035	MMSL
399943	MMSL
51626	MMSL
d04976	MMSL
007561	NDDF
329482000	SNOMEDCT_US
396011004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Deferiprone	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0576	TABLET, COATED	500 mg	ORAL	ANDA	28 sections
Deferiprone	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0711	TABLET, COATED	1000 mg	ORAL	ANDA	28 sections
FERRIPROX	HUMAN PRESCRIPTION DRUG LABEL	1	10122-100	TABLET, FILM COATED	500 mg	ORAL	NDA	28 sections
FERRIPROX	HUMAN PRESCRIPTION DRUG LABEL	1	10122-100	TABLET, FILM COATED	500 mg	ORAL	NDA	28 sections
FERRIPROX	HUMAN PRESCRIPTION DRUG LABEL	1	10122-101	SOLUTION	100 mg	ORAL	NDA	29 sections
FERRIPROX	HUMAN PRESCRIPTION DRUG LABEL	1	10122-103	TABLET, FILM COATED	1000 mg	ORAL	NDA	29 sections
FERRIPROX	HUMAN PRESCRIPTION DRUG LABEL	1	10122-104	TABLET	1000 mg	ORAL	NDA	29 sections
Deferiprone	HUMAN PRESCRIPTION DRUG LABEL	1	51672-4196	TABLET	500 mg	ORAL	ANDA	32 sections
Deferiprone	HUMAN PRESCRIPTION DRUG LABEL	1	51672-4237	TABLET	1000 mg	ORAL	ANDA	32 sections
FERRIPROX	HUMAN PRESCRIPTION DRUG LABEL	1	52609-0006	TABLET, FILM COATED	500 mg	ORAL	NDA	28 sections
FERRIPROX	HUMAN PRESCRIPTION DRUG LABEL	1	52609-0007	TABLET, FILM COATED	1000 mg	ORAL	NDA	29 sections
DEFERIPRONE	HUMAN PRESCRIPTION DRUG LABEL	1	75907-348	TABLET, COATED	1000 mg	ORAL	ANDA	25 sections
DEFERIPRONE	HUMAN PRESCRIPTION DRUG LABEL	1	75907-349	TABLET, COATED	500 mg	ORAL	ANDA	25 sections